Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).

@article{Lee2016ComparisonOW,
  title={Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).},
  author={Ji Yun Lee and Jong-Mu Sun and Dongryul Oh and Sung Hee Lim and Juna Goo and Se-Hoon Lee and Sung-Bae Kim and Keon Uk Park and Hoon-Kyo Kim and Dae Sik Hong and Jun Suk Kim and Seong-Geun Kim and Seong Yoon Yi and Hwan-Jung Yun and Myung Soo Hyun and Hyo Jung Kim and Sin-Ho Jung and Keunchil Park and Yong Chan Ahn and Myung-Ju Ahn},
  journal={Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  year={2016},
  volume={118 2},
  pages={
          244-50
        }
}
  • J. Lee, Jong-Mu Sun, M. Ahn
  • Published 1 February 2016
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort
TLDR
IMRT concurrent with a weekly cisplatin regimen was associated with significantly improved distant metastasis-free survival in locally advanced NPC, and differences in the selected acute toxicities between the weekly and triweekly concurrent cis Platin regimens were noted.
A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
TLDR
Once-every-3-weeks cisplatin as concurrent chemoradiotherapy is noninferior to once-a-week cisplasin in the treatment efficacy in the LANPC, although both regimens are well tolerated.
Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy
TLDR
Cisplatin at a dose of 30 mg/m2 administered weekly concurrent with intensity-modulated radiotherapy (IMRT) was used to treat locally advanced NPC with resistance to neoadjuvant chemotherapy based on cisplatin to improve the prognosis.
Weekly cisplatin with radiotherapy for locally advanced head and neck squamous cell carcinoma.
TLDR
This study shows that a median cumulative dose of 200 mg/m2 cisplatin can be safely administered using a weekly regimen to patients treated with concomitant RT (CFRT or ART).
Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
TLDR
Compared with Triweekly cisplatin regimen, Weekly regimen may be a better choice during CCRT, and the incidence rate of acute toxicities was similar between the groups.
Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis
TLDR
Both weekly and triweekly schedules could be recommended to NPC patients during CCRT, and hematologic adverse Events in weekly strategy and non-hematologic adverse events in triweekly strategy are of higher concern.
Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
TLDR
Concurrent chemoradiotherapy using weekly cisplatin at 40mg/m2 per week is an effective, well tolerated regimen allowing most patients to receive at least 5 cycles of chemotherapy, but a phase III randomized control trial is needed to establish the long term clinical outcome.
Concurrent chemoradiation in head and neck cancers with weekly cisplatin: analysing toxicities
Background: Head and neck cancers constitute 6% of cancers worldwide. The management requires a multidisciplinary approach. Concomitant chemoradiotherapy with cisplatin is the standard approach for
Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
TLDR
Patients should be given specific attention during concurrent chemoradiotherapy, particularly in the presence of previous induction chemotherapy, as concurrent platinum treatment and induction chemotherapy were risk factors of developing grade 3/4 hematological toxicities.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial.
  • A. Chan, P. Teo, P. Johnson
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Although PFS was not significantly different between the concurrent CRT arm and the RT-alone arm in the overall comparison, P FS was significantly prolonged in patients with advanced tumor and node stages.
The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity
TLDR
Three-weekly high-dose cisplatin treatment showed higher compliance, and lower acute toxicity compared to weekly low- doses of cis Platin, which was also shown to be effective in patients with high-risk oral squamous cell carcinoma.
Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.
  • J. Wee, E. Tan, D. Machin
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
It is confirmed that chemotherapy improves the distant metastasis control rate in NPC and its applicability to endemic NPC is demonstrated.
Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK
TLDR
Delivery of 100 mg/m2 Cisplatin 3-weekly with radiotherapy was less tolerated than 40 mg/ m2 weekly and resulted in less patients achieving cumulative dose beyond 200 mg/M2, potentially lowering chemotherapy dose intensity.
Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.
TLDR
It is concluded that CCRT is superior to RT alone for patients with advanced NPC in endemic areas.
The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck
TLDR
A randomized phase III trial is required to confirm the safety and efficacy of weekly cisplatin therapy in patients with poor PS and/or older age at diagnosis and statistically similar response rates and adverse event profile.
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
  • Anne W. M. Lee, W. Lau, J. Lau
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites, however, there was significant increase in the risk of toxicities and no early gain in overall survival.
Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.
  • M. al-Sarraf, M. Leblanc, J. Ensley
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
It is concluded that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival.
A preliminary result of concurrent chemoradiation with weekly cisplatin in elderly nasopharyngeal carcinoma patients
Conclusion. A weekly regimen of cisplatin 30 mg/m2 as concurrent chemoradiation (CCRT) was effective in elderly nasopharyngeal carcinoma (NPC) patients, with acceptable and reversible acute toxicity
...
...